Experimental models have evaluated it for cytoprotective and regenerative activities across gastrointestinal mucosa, tendons, ligaments, muscles, bone, nervous tissue, and vascular endothelium
If we conflate access to drugs with access to quality multidisciplinary care, were going down the wrong path altogether
Phase 1 GLP-1 and GLP-1/GIP receptor agonists should be used as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight maintenance, in: BMI 38 kg/m 2 (or 35 kg/m 2 in ethnic groups known to be at equivalent risk of obesity consequences at lower BMI than White ethnicity), and one or more obesity-related clinical condition, or Edmonton Obesity Staging System stage 3 or 4 (see Box 1
PEG-MGF and MGF are classified as prohibited substances under WADA anti-doping regulations and are not approved for use in competitive sport